Breast cancer heterogeneity and response to novel therapeutics
Simple Summary Breast cancer is a heterogeneous disease that is driven by genetic,
epigenetic and phenotypic modifications and is also affected by the microenvironment and …
epigenetic and phenotypic modifications and is also affected by the microenvironment and …
Transposons: Unexpected players in cancer
RK Pradhan, W Ramakrishna - Gene, 2022 - Elsevier
Transposons are repetitive DNA sequences encompassing about half of the human
genome. They play a vital role in genome stability maintenance and contribute to genomic …
genome. They play a vital role in genome stability maintenance and contribute to genomic …
[HTML][HTML] Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest …
R Thomas, CA Wiley, EL Droste, J Robertson… - PLoS …, 2023 - journals.plos.org
Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC)
harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found …
harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found …
Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
Z Liu, L Liu, D Jiao, C Guo, L Wang, Z Li, Z Sun… - Frontiers in …, 2021 - frontiersin.org
Background: Esophageal adenocarcinoma (EAC) remains a leading cause of cancer-
related deaths worldwide and demonstrates a predominant rising incidence in Western …
related deaths worldwide and demonstrates a predominant rising incidence in Western …
Bioinformatic analysis of immune significance of RYR2 mutation in breast cancer
Z Xu, L ** Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers
EC Morafraile, C Saiz-Ladera, C Nieto-Jiménez… - Current …, 2023 - mdpi.com
Simple Summary The identification of novel therapeutic strategies for Colorectal Cancer
(CRC) patients with BRAF mutations is mandatory, since most of the current treatments …
(CRC) patients with BRAF mutations is mandatory, since most of the current treatments …